ARLINGTON HEIGHTS, IL — In a move designed to harmonize regulatory requirements with the practical realities of the operating room, the Breast Surgery Collaborative Community (BSCC) has officially submitted a proposal to the U.S. Food and Drug Administration (FDA) to revise the Breast Implant Patient Decision Checklist. This initiative, now open for public comment, marks a pivotal moment in the ongoing effort to balance rigorous informed consent with patient-centered communication.
For years, the intersection of patient safety, regulatory oversight, and surgical efficacy has been a focal point for the plastic surgery community. By engaging in a transparent, consensus-based revision process, the BSCC aims to transform a document that many have criticized as overly cumbersome into a vital, clear, and actionable tool for women considering breast implant surgery.
The Genesis of the Checklist: A Chronology of Implementation
To understand the necessity of this proposal, one must first look at the history of the FDA’s involvement in breast implant labeling.
2019–2021: The Regulatory Shift
In response to growing public discourse regarding the safety profiles of breast implants, the FDA initiated a series of regulatory updates. Central to these was the mandate for a "Patient Decision Checklist." The intention was to ensure that patients were not merely signing a standard informed consent form, but were actively engaging with a document that highlighted specific risks—such as Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) and Breast Implant Illness (BII) symptoms—in a format that required individual acknowledgement.
2022: Implementation and Growing Pains
When the checklist was officially implemented in 2022, the surgical community largely welcomed the emphasis on transparency. However, the reality of clinical implementation proved difficult. Surgeons reported that the length and complexity of the document frequently overwhelmed patients during the consultation process, often detracting from the qualitative, nuanced conversation that should characterize the patient-physician relationship.
2023–2024: The Collaborative Effort
Recognizing these challenges, the BSCC—a coalition comprised of board-certified plastic surgeons, patient advocates, and industry representatives—began a formal review process. Throughout 2024, the group convened to evaluate the checklist line-by-line, seeking to strip away redundant information while maintaining the high standards of safety transparency demanded by the FDA.
The Case for Change: Why Length Does Not Equal Clarity
The primary criticism of the existing 2022 checklist has been its "educational friction." In clinical settings, the goal is to achieve true shared decision-making. When a patient is handed a document that is perceived as a legalistic hurdle rather than an educational guide, the efficacy of the communication drops.
The Patient-Centered Perspective
Patient advocates, who have been instrumental in this revision process, have argued that a "shorter, more concise checklist" is not merely about convenience; it is about cognitive accessibility. When a document is too long, the essential safety information can be lost in the noise. By condensing the checklist, the BSCC believes that patients will be more likely to read, understand, and discuss the content during their pre-surgical appointments.
Bridging the Gap in Shared Decision-Making
Shared decision-making requires that the patient and the physician are operating from a common understanding of risks and benefits. The BSCC’s proposed revisions focus on:
- Synthesizing Information: Reducing technical jargon without sacrificing clinical accuracy.
- Formatting for Readability: Utilizing clearer visual cues and bulleted summaries that align with modern health literacy standards.
- Integrating with Informed Consent: Ensuring the checklist serves as a supplement to, rather than a duplicate of, standard surgical consent documents.
Supporting Data: A Consensus-Based Approach
The BSCC’s proposal is unique because of its multi-stakeholder origin. The drafting committee included representatives from:
- The American Society of Plastic Surgeons (ASPS)
- The Aesthetic Society
- Breast Implant Safety Alliance (BISA)
- The Plastic Surgery Foundation (PSF)
- Manufacturer representatives (Mentor, Establishment Labs, and Sientra)
By bringing manufacturers into the fold alongside patient advocates and surgeons, the BSCC ensured that the proposed changes are not only medically sound but also compliant with the regulatory data that manufacturers are required to share. This consensus-based approach acts as a safeguard against potential biases, ensuring that the revised document represents a balanced, industry-wide agreement on what is necessary for patient safety.
The Role of the FDA Collaborative Community Framework
The BSCC operates under the FDA’s "Collaborative Community" framework—a model designed to foster cooperation between the public and private sectors to solve complex regulatory challenges. Unlike a traditional lobby or trade group, the BSCC functions as a forum for continuous dialogue.
The FDA’s endorsement of this collaborative approach signals an openness to "real-world" feedback. By submitting the revision to the public docket, the BSCC is inviting a "stress test" of their proposal. This allows the agency to see how the broader public, beyond the surgical community, responds to the changes.
Implications for the Future of Plastic Surgery
If adopted, the revised checklist could set a new standard for how medical devices are discussed in the office.
1. Clinical Efficiency
For surgeons, a streamlined checklist means more time spent on patient-specific concerns, such as anatomy, aesthetic goals, and psychological readiness, rather than administrative paperwork. This shift could improve the overall quality of the consultation experience.
2. Enhanced Patient Autonomy
The goal of informed consent is autonomy—ensuring the patient has the right and the capacity to make a decision based on clear, digestible information. By removing the "clutter" from the current document, the revised version empowers patients to identify the specific risks that concern them most, fostering a more targeted dialogue.
3. Regulatory Precedent
The success of this initiative could serve as a blueprint for other medical specialties. If the BSCC can successfully refine a document mandated by the FDA through a collaborative, multi-stakeholder process, it may provide a roadmap for updating other complex patient-education requirements in cardiology, orthopedics, and beyond.
How to Participate in the Public Comment Period
The BSCC, the FDA, and patient advocacy groups are urging all interested parties to review the proposed document. Participation in this process is a vital part of democratic medical governance.
- Deadline: December 1, 2026.
- Submission Link: FDA Public Docket: FDA-2019-D-4467-1386
- Requirement: When submitting, users must include the tracking number mt7-xgl2-2crx. This ensures that the comment is indexed correctly as part of the BSCC’s specific proposal.
Constructive feedback is particularly encouraged from patients who have previously undergone breast implant surgery, as their experiences with the original 2022 checklist provide the most valuable data on its usability.
Conclusion: A Commitment to Continuous Improvement
The proposal to revise the Breast Implant Patient Decision Checklist is not a retreat from safety, but rather an evolution of it. As medicine advances, so too must the tools we use to educate and protect patients. By prioritizing clarity, brevity, and collaboration, the Breast Surgery Collaborative Community is demonstrating that the best regulatory outcomes occur when patients, surgeons, and regulators sit at the same table.
As the December 2026 deadline approaches, the plastic surgery community awaits the FDA’s response. Should the proposal be accepted, it will mark a significant victory for patient-centered care, proving that when stakeholders work together, the complex intersection of surgery and regulation can be navigated in a way that truly serves the public interest.
Appendix: Participating Organizations and Representatives
The following individuals and organizations represent the consensus-driven nature of the BSCC:
- Medical Societies: William P. Adams Jr., MD (The Aesthetic Society); Scot B. Glasberg, MD, George Chatson, MD, Lynn Damitz, MD (ASPS/PSF); Melinda Haws, MD, Patricia McGuire, MD (The Aesthetic Society); Debra Johnson, MD (At Large PS Representative).
- Patient Advocates: Jennifer Cook (BISA); Amanda Hynum (OHSU); Cynthia Johnson, RN; Meristacia Kingston, MD; Kimberly Platt, MSN, RN, CAPA; Briana Theroux.
- Industry (Non-Voting): Sheryl Robinson-Collins (Mentor Worldwide LLC); Margie Rose, MPH (Establishment Labs/Motiva); Sara Saul, PhD (Tiger Aesthetics/Sientra).
- Ex-Officio: Jamil Ahmad, MD (Aesthetic Society President); C. Bob Basu, MD, MBA, MPH, FACS (ASPS President).
The BSCC continues to welcome the participation of all stakeholders committed to the safe, transparent, and equitable delivery of breast surgery care.
About the Author
